|Bid||95.00 x 900|
|Ask||95.30 x 800|
|Day's Range||94.94 - 96.96|
|52 Week Range||58.23 - 97.22|
|Beta (3Y Monthly)||1.19|
|PE Ratio (TTM)||11.61|
|Earnings Date||Oct 31, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||89.58|
Stock of The Day: Cigna battled doubters for months over its $67 billion Express Scripts takeover. Now, as the deal is almost done, Cigna stock is near a buy point.
Express Scripts Holding Co, one of the largest U.S. prescription benefits managers, will cover new migraine drugs from Eli Lilly and Amgen Inc, but exclude a rival medication from Teva Pharmaceutical Industries Ltd after price negotiations with all three manufacturers. The decision represents a setback for Israel-based Teva , which is in the midst of a corporate restructuring and had hoped to capture a sizable share of the multibillion-dollar migraine market. Express Scripts is also taking steps to limit use of the Amgen and Lilly migraine drugs to patients it says are most likely to benefit from them.
CVS CEO Larry Merlo outlined his vision for the combined company earlier this month — a new data-driven health-care model that's more personal, convenient and tailored to individual patients than ever before.
Express Scripts' (ESRX) Medicare PDP to initiate coverage from Jan 1, 2019. The plan includes Walmart along with CVS Pharmacy and the Kroger Family of Pharmacies.
Jim Cramer opines on callers' favorite stocks at lightning speed, including a health-care play being absorbed by Cigna.
IBD Stock Of The Day: Centene has a new buy point after rallying from an April breakout. Managed care stocks have been winners in 2018, and are holding up well now.
Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc.(IONS), announced today that they are working together with Accredo® specialty pharmacy, a subsidiary of Express Scripts (ESRX), to distribute TEGSEDI™ (inotersen) subcutaneous injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. Approved by the U.S. Food and Drug Administration (FDA) today, TEGSEDI is the first and only subcutaneous RNA-targeting therapeutic offering patients an effective treatment for the polyneuropathy of hATTR amyloidosis.
Carl Icahn recently tried to destroy Cigna's $54 billion purchase of Express Scripts by buying shares of Cigna and pushing it to get out of the deal. Usually shares of an acquiring company fall and those of a target rise, allowing traditional merger arbitrage traders the chance to profit on their price movements as the deal nears completion. Carl Icahn recently used it to try to destroy Cigna CI 's $54 billion purchase of Express Scripts ESRX .
So-called activist arbitrageurs create an extra, risk-adjusted, 5.7 percent bounce in the shares of acquirers, researchers at Columbia University and the University of Florida say.
NEW YORK, Sept. 28, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
The companies say the transaction is contingent on regulatory approval from the Trump administration for CVS Health's $69 billion acquisition of Aetna.
The decision bodes well for the pending U.S. antitrust review of CVS Health Corp's (NYSE:CVS - News) proposed $69 billion acquisition of health insurer Aetna Inc (NYSE:AET - News). The new company will marry Cigna's business of managing health plans for corporations and the government with Express Scripts' (NasdaqGS:ESRX - News) role handling pharmacy benefits for those same customers.
The U.S. Department of Justice has cleared Cigna's acquisition of Express Scripts, the companies announced in a statement Monday. Shareholders voted to approve the merger last month, despite opposition from activist investor Carl Icahn. The U.S. Department of Justice has cleared Cigna CI 's $52 billion acquisition of Express Scripts ESRX , the companies announced in a statement Monday.
Anthem stock is surging from buy zone after several weeks of tight trading. As IBD founder William J. O'Neil mused, constructive patterns often have periods of tight trading.